Interaction of the Duffy binding protein (DBP) with its erythrocyte receptor is critical for maintaining Plasmodium vivax blood-stage infections, making DBP an appealing vaccine candidate. The cysteine-rich region II is the ligand domain of DBP and a target of vaccine development. Interestingly, most of the allelic diversity observed in DBP is due to the high rate of nonsynonymous polymorphisms in this critical domain for receptor recognition. Similar to the hypervariability in influenza hemagglutinin, this pattern of polymorphisms in the DBP ligand domain suggests that this variation is a mechanism to evade antibody neutralization. To evaluate the role that dbp allelic diversity plays in strain-specific immunity, we examined the ability of an anti-Sal1 DBP serum to inhibit the erythrocyte-binding function of variant dbp alleles expressed on COS cells. We observed that the PNG-7.18 allele was significantly less sensitive to immune inhibition of its erythrocytebinding activity than were the Sal1 and PNG-27.16 alleles. This result suggested that the unique polymorphisms of resistant PNG-7.18 were part of a protective epitope on the DBP ligand. To confirm this, Sal1 was converted to the refractory phenotype by introduction of 3 polymorphisms unique to PNG-7.18, via site-directed mutagenesis. The results of the present study indicate that linked polymorphisms have an additive, synergistic effect on DBP antigenic character.
Malaria is a serious public health problem throughout much of the developing world. In both temperate and tropical regions, Plasmodium vivax malaria takes an enormous toll in the form of human suffering and economic losses. The Duffy binding protein (DBP) of P. vivax (PvDBP) is an important antimalaria vaccine candidate because interaction of PvDBP with its receptor on host erythrocytes is required for merozoite invasion, which leads to blood-stage development of the parasite [1] . DBP is a member of the Duffy binding-like (DBL) erythro-cyte-binding protein family expressed in the micronemes of P. vivax and P. knowlesi merozoites [2] . DBP is a 140-kDa type 1 integral membrane protein and is expressed during late schizont development [3] [4] [5] . The DBP ligand recognizes the N-terminal extracellular domain of the Duffy blood group antigen as its receptor on the erythrocyte surface.
Region II of DBP (DBP II ) functions as the ligand domain, and binding activity within this region has been localized to a segment between cysteines 4 and 7. The action of this binding motif of DBP is critical, yet the motif is hypervariable with polymorphisms frequent at certain residues [6] [7] [8] [9] [10] . This pattern of excessive polymorphisms is consistent with a high selection pressure on DBP and suggests that allelic variation functions as a mechanism of immune evasion. Naturally occurring antibodies to DBP are prevalent in individuals living in areas where malaria is highly endemic [11] , and several studies have identified forces of selection operating on functional domains of PvDBP [6, 10, 12, 13] . The gene for P. vivax dbp region II has a high ratio of nonsynonymous to synonymous mutations, which further supports the hypothesis that positive selection for amino acid polymorphism acts on this domain [13] . Polymorphisms in DBP cluster within the ligand domain, which suggests that this diversity results from immune selection pressure [6] . This pattern of polymorphisms has been confirmed in studies of DBP II that were conducted in geographically disparate areas [7] [8] [9] . Preliminary work has shown no significant differences in binding between allelic types of DBP II [8] .
Several lines of evidence support the function of variation in DBP II as a mechanism of immune evasion. Residues in the central section (region II.2) of the critical binding segment in DBP II are hypervariable. A study of dbp alleles from P. vivax isolates from Papua New Guinea (PNG) found that region II.2 of dbp showed a substitution rate 4 times greater than that of the rest of the domain and 10 times greater than that found within the dbp gene overall [6] . In an analysis of samples from multiple studies conducted in Colombia and PNG, 93% of DBP polymorphisms were found within the central segment of region II, between cysteines 4 and 7 [8] .
To investigate the significance of allelic diversity in the DBP ligand and its potential relationship to strain-specific anti-DBP immune inhibition, dbp alleles from 2 P. vivax isolates from the north coast of PNG were cloned. The alleles selected were dbp PNG-7.18 and PNG-27.16, which belong to discrete allelic families PNG-b and PNG-a, respectively, and differ, within the critical receptor recognition region of the DBP ligand domain, at multiple codons from the P. vivax laboratory reference clone Sal1 [10] (figure 1). Of importance, dbp PNG-7.18 contains 3 polymorphisms (at DBP residues 417, 437, and 503), which we observed to be linked in multiple dbp alleles.
The erythrocyte-binding activity of DBP was quantified by use of an in vitro cytoadherence assay of transiently transfected COS7 cell monolayers [15] . By use of this assay, anti-DBP immune inhibition can be measured by adding serum to the culture medium [16] . Anti-Sal1 DBP serum was tested for inhibition of erythrocyte binding by the PNG allelic variants, compared with that by the Sal1 allele. Antiserum inhibited erythrocyte binding of DBP variants in a strain-specific manner.
Through site-directed mutagenesis (SDM), variant residues that altered immune inhibition of DBP binding were identified. Certain polymorphisms had an additive effect in significantly reducing immune inhibition of DBP binding. Previously, there has been no proof that single-amino acid changes alter immune recognition of a malarial antigen. In the present study, we observed that individual polymorphisms in DBP alter antigenic character and that, in combination, they cause significant changes in sensitivity to immune inhibition. This is the first demonstration of strain specificity in the response against DBP and the first direct evidence that single-amino acid substitutions alter the antigenic character of a malarial antigen.
MATERIALS AND METHODS
DBP-pEGFP constructs. DBP II has previously been subcloned into the pEGFP-N1 plasmid, with a flanking signal sequence from the herpes simplex virus glycoprotein D1 [15, 16] . This targeted expression to the surface of the transfected COS cells as a green fluorescent protein (GFP) fusion protein. To generate additional GFP constructs with different DBP sequences within region II, a 561-bp fragment cut by the restriction enzymes EcoRV and KpnI (aa 288-474 within region II) from pEGFP/ DBPSal-1 was removed, and the corresponding EcoRV-KpnI fragments from pCR2.1DBP27.16 and pCR2.1DBP7.18 were subcloned, creating pEGFP/DBP-27.16 and pEGFP/DBP-7.18 [13] . The isolated PNG-7.18 strain, which is identical to PNG-7.3, also contained a TrA mutation in codon I503K outside of the subcloned region. This mutation was introduced by SDM (by use of primers 5 -CTGTCAAATAAATTCAAAAGTGTAA-AAAACGCAGAAAAGGTTCAG-3 and 5 -CTGAACCTTTTC-TGCGTTTTTTACACTTTTGAATTTATTTGACAG-3 ) to create pEGFP/DBP-7.18. Recombinant plasmids were purified by use of an endotoxin-free plasmid DNA purification system (Qiagen).
Generation of rabbit anti-DBP serum. Antiserum to C1 recombinant protein (DBP II-IV ) was produced as described elsewhere [17] . Two rabbits were immunized with purified recombinant proteins, in accordance with approved protocols. For the first injection, 100 mg in solution was emulsified in Freund's complete adjuvant and administered subcutaneously (sc). To boost the antibody response, the antigen was emulsified in Freund's incomplete adjuvant, and rabbits were vaccinated sc at 2-week intervals 5 times. Ten days after the last immunization, serum samples were collected from clotted blood, decomplemented, aliquoted, and stored at Ϫ20ЊC or Ϫ80ЊC.
COS cell transfection, binding assays, and inhibition of binding with serum. Recombinant plasmids were transfected into COS7 cells by use of lipofectamine reagent (Gibco/BRL). COS7 cells were seeded in serum-free Dulbecco's MEM (DMEM) at 50-60 cells/field of view (magnification, ϫ200) and incubated for 3 h at 37ЊC. A 3% solution of lipofectamine was mixed with endotoxin-free water (Sigma), was incubated for 15 min, and was mixed with an equal volume of endotoxin-free water containing 0.1 mg of plasmid DNA. After a 20-min incubation, this mixture was added to serum-free DMEM, was mixed by pipetting, and was placed over adherent COS7 cells. Transfected cells were incubated at 37ЊC in 5% CO 2 . Sixteen hours after transfection, media were replaced with DMEM plus 10% fetal bovine serum.
Forty-two hours after transfection, antiserum was added at inhibition and I R were evaluated by 1-way analysis of variance (ANOVA) and Tukey's posttest. I R values were transformed by the arcsin function before statistical calculations.
Primer design for SDM. Primers were designed to be 25-45 bp in length, with a GC content of у40%. When possible, the 3 end of a primer terminated in у1 G or C base. The target melting temperature was у75ЊC by the following formula: melting temperature p 81.5 + 0.41(percentage GC)Ϫ675/ NϪpercentage mismatch, where N is primer length.
SDM. SDM was conducted according to the Stratagene QuikSite kit (Stratagene) protocol. Complementary primer pairs were designed to contain the desired nucleotide changes for chosen mutation sites in dbp. The pEGFP-N1/DBP II construct was used as a template for mutagenesis reactions. Reaction mixes contained 50-100 ng of template, 125 ng of each primer, 2.5 U of Pfu Turbo polymerase, 1ϫ reaction buffer, and 10 mmol/L dNTP (2.5 mmol/L each). Thermocycling was performed by use of the following conditions: 3 min at 94ЊC, followed by 16-18 cycles of 30 s at 94ЊC, 1 min at 55ЊC, and 12 min 24 s at 72ЊC. Reaction products were digested for 2-4 h with 2.5 U of DpnI, which is specific for methylated DNA. This step selected for newly generated mutant DNA strands by specifically cleaving nonmutant parental template strands. Constructs were sequenced by use of an ABI 3700 system.
RESULTS
Association of DBP II polymorphisms in P. vivax isolates from PNG. In DBP from P. vivax isolates from PNG, the variants N417K, W437R, and I503K more frequently occur together than separately (figure 1). Frequency of occurrence was compiled from 3 previous studies [6, 8, 10] . In 69 DBP II samples from different geographic areas of PNG, the N417K variant occurred in conjunction with polymorphism W437R in all cases. Similarly, W437R occurred in combination with either N417K or I503K in all isolates. The I503K polymorphism occurred separately from the other 2 in only 15.8% of DBP II samples. These variants thus represent a putative linkage group. The apparent association of the occurrence of this trio of polymorphisms suggests a synergistic functional effect.
Anti-DBP serum inhibition of binding of variant DBP II alleles. Rabbit antiserum prepared against the Sal1 DBP was tested for its ability to inhibit erythrocyte binding of DBP variants PNG-7.18 and PNG-27.16. These variant residues had been predicted as unlikely to be involved in erythrocyte binding, by use of the SIFT program, which is an algorithm used to identify residues that tolerate polymorphisms, by weighing factors such as frequency of occurrence of a variant among isolates, as well as conserved versus radical amino acid substitutions [14] . This prediction was confirmed experimentally by the COS7 erythrocyte-binding assay, in which there was no significant difference in the erythrocyte-binding activity of the 3 alleles and their levels of expression were equivalent (figure 2). The serum differentially inhibited binding of the PNG allelic variants, compared with the Sal1 allele. Anti-Sal1 DBP serum inhibited Sal1 DBP binding by a mean of 59.8% (SE, 2.8%) ( figure 3 A second set of SDM constructs was tested to investigate which of the variant residues in the PNG-7.18 allele mediated the observed enhanced refractoriness to anti-Sal1 DBP inhibition. Assay results are shown as a relative I R , which represents the ratio of values of serum inhibition against each mutant DBP type, compared with that of the Sal1 allele. The singleresidue DBP variants, N417K, W437R, and I503K, had slightly decreased sensitivity to serum inhibition of erythrocyte bind- Polymorphisms from a linked trio found in the PNG-7.18 allele were tested, singly and in combination, within a Sal1 background. These variant residues differentially altered recognition of DBP by antiserum. Mutant alleles are shown along an axis of decreasing serum inhibition. Alleles within the red and blue shaded circles grouped statistically with that parent allele, whereas the intermediate group is not significantly different from either wildtype (wt) Sal1 or PNG-7.18. The inhibition ratio of the combined W437R/I503K pair of PNG-7.18 polymorphisms closely matched that of the wt PNG-7.18 allele, illustrating the importance of these 2 codons in determining the antigenic character of DBP, as recognized by serum against rDBP.
ing, compared with that of the Sal1 allele, with I R values of 0.92 (SE, 0.026), 0.83 (SE, 0.061), and 0.83 (SE, 0.072), respectively (figure 4). In contrast, the site-directed mutant allele containing the K386Q variant showed a slight increase in sensitivity to serum inhibition of erythrocyte binding, compared with that of the Sal1 allele, with an I R value of 1.12 (SE, 0.059). Combinations of 2 and 3 variant residues (N417K, W437R, and I503K) in SDM constructs were compared to Sal1 for relative inhibition in the in vitro erythrocyte-binding assay ( figure 4) . SDM variants N417K/W437R and N417K/I503K followed the trend toward increased refractoriness to anti-Sal1 inhibition, with I R values of 0.71 (SE, 0.112) and 0.835 (SE, 0.035), respectively. The combinations of polymorphisms W437R/I503K and N417K/ W437R/I503K showed significant ( ) increases in refrac-P ! .05 toriness to inhibition, compared with that of the Sal1 allele, with I R values of 0.68 (SE, 0.116) and 0.67 (SE, 0.05), respectively, and the I R values of these mutant alleles were not significantly different from those of the wild-type (wt) PNG-7.18 allele (figures 4 and 5).
DISCUSSION
PvDBP is an important antimalaria vaccine candidate because interaction of PvDBP with its receptor on host erythrocytes is required for merozoite invasion, which leads to blood-stage development of the parasite [1] . The action of the binding motif of DBP is critical, yet the motif is hypervariable, with polymorphisms frequent at certain residues [6] [7] [8] [9] [10] . This pattern of excessive polymorphisms is consistent with a high selection pressure on DBP and suggests that allelic variation functions as a mechanism of immune evasion. In the present study, antiSal1 DBP serum was tested against 3 variant DBP II alleles. Inhibition of binding of the PNG-7.18 allele was significantly lower than inhibition of binding of the Sal1 DBP II . This result indicates that polymorphisms in the 4 codons that differ between the PNG-7.18 allele and the Sal1 allele (aa 386, 417, 437, and 503) form part of dominant neutralizing epitopes that can change DBP antigenic character to the extent of compromising efficiency of immune inhibition.
To determine which residues of the DBP ligand domain mediated the difference observed in antibody recognition, constructs containing each unique variant residue of PNG-7.18 singly against a Sal1 background were produced by SDM. The mutagenesis method was used to create single-residue DBP variants at the polymorphic codons that differ between the PNG-7.18 allele and the Sal1 and PNG-27.16 alleles (aa 386, 417, 437, and 503). Antiserum inhibition of mutant alleles containing PNG-7.18 residues within a Sal1 background identified a trio of polymorphic variants (N417K, W437R, and I503K) responsible for altering the antigenic character of the PNG-7.18 allele. Although each single-amino acid change decreased sensitivity to immune inhibition, which paralleled the trend seen with the wt PNG-7.18 allele, none matched the extent of refractoriness to immune inhibition exhibited by the intact allele. These experiments point to an important role for the linked trio of polymorphisms-particularly for residues 437 and 503-in immune recognition of DBP.
Overall, these results indicate that polymorphisms in the DBP ligand domain can alter the efficacy of an acquired inhibitory immune response. This is consistent with the model of positive selection exemplified by influenza hemagglutinin (HA). Polymorphisms in HA cluster around residues critical for binding and function as a mechanism of immune evasion. Positive selection favors variation in residues within epitopes that change the antigenic character of the molecule to abrogate immune inhibition without having a negative effect on its ligand function [17] [18] [19] [20] . DBP II would not be expected to have a similar structure to influenza HA, since the former binds to a globular protein receptor, as opposed to a carbohydrate receptor for HA, and the DBL domains are expected to have a novel fold. Nonetheless, the localized nature of polymorphisms within the critical binding area for both DBP II and HA suggests that they share a similar mechanism of evading host antibody response.
The existence of strain specificity in the antibody response to PvDBP has implications for development of a vaccine against the parasite, underscoring the need for rational vaccine design. It is important that such a significant change in antigenic character can be mediated by relatively few variant residues within the critical binding region of the ligand domain, since polymorphisms are numerous in this region of DBP. Further work will be necessary to identify the main epitopes recognized by naturally acquired antibodies to DBP in humans and to identify conserved, functionally important epitopes that might elicit antibodies that inhibit binding of DBP to its erythrocyte receptor. It seems likely that the residues identified in the present study form part of a discontinuous epitope adjacent to the receptorbinding region. Elucidation of the structure of the PvDBP ligand domain will be vital for understanding the relative importance of residue diversity in critical epitopes within DBP.
Genome analysis of malaria parasites has revealed that nucleotide polymorphisms are nonrandomly distributed and that excess polymorphisms occur in membrane proteins [21, 22] . This phenomenon is consistent with the essential functional roles of many malarial membrane proteins that have surface-exposed extracellular domains [12, 23, 24] , especially in the invasive merozoite. Indeed, many of the leading blood-stage vaccine candidates are membrane proteins either positioned on the merozoite surface or released onto the surface from apical organelles during invasion of erythrocytes [25] [26] [27] . There is accumulating evidence from molecular population genetic analyses that diversifying selection occurs in such important functional domains of Plasmodium proteins [6, 12, [28] [29] [30] . Our study has demonstrated that naturally occurring polymorphisms in DBP can confer significant differences to inhibition by serum antibodies. This is the first direct experimental evidence that single-amino acid substitutions alter the antigenic character of a malarial antigen. These data provide empirical evidence for the hypothesis that immune selection is a driving force for allelic diversity in malaria parasites.
